Endpoints News ٢٣ فبراير ٢٠٢٦ Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial المصدر